New quadrivalent flu vaccine shows promise for little ones
NCT ID NCT04381689
First seen Jun 24, 2026 · Last updated Jul 09, 2026 · Updated 4 times
Summary
This phase 3 study tests a new quadrivalent seasonal influenza vaccine in healthy infants aged 6 months to under 3 years. The goal is to see if the vaccine triggers a strong immune response and is safe compared to an existing flu shot. About 245 children will take part, and researchers will measure antibody levels before and after vaccination.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- quadrivalent seasonal influenza vaccine
- What this could lead to
- If successful, this could provide a safe and effective seasonal flu vaccine option for infants and toddlers.
- What could go wrong
- This is a mid-stage trial with 245 participants, so results may not apply to all children. The vaccine may not work as well as expected or could cause side effects like mild fever or soreness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
260 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Oct 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 months to 3 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Healthy infants 'from 6 months to under 3 years of age (≥6 months and \<3 years) 2. Born after normal gestation period (which is more than 37 weeks) 3. A subject's legally acceptable representative has voluntarily decided on participation and provided written informed consent after receiving and understanding a detailed explanation on this study Exclusion Criteria: 1. A history of severe hypersensitivity reactions (e.g., anaphylaxis) to eggs, chicken, and other components of a vaccine including those derived from chicken 2. A history of influenza vaccination within 6 months prior to screening 3. Immuno dysfunction including immunodeficiency diseases or a family history thereof 4. A history of Guillain-Barre syndrome 5. Down's syndrome or cytogenetic disorders 6. Severe chronic diseases (e.g., cardiovascular diseases excluding controlled hypertension, respiratory diseases with respiratory failure, metabolic diseases, renal dysfunction, hemoglobinopathy, etc.) that, in the opinion of investigator, preclude a subject's participation in the study 7. Risk of serious bleeding from an IM injection such as hemophilia patients or those on anticoagulants 8. Acute fever with body temperature exceeding 38.0℃ within 72 hours prior to vaccination with the IP 9. Vaccinated with other vaccines within 28 days prior to screening 10. Received immunosuppressants or immune-modifying drugs within 3 months prior to screening ① Azathioprine, cyclosporin, interferon, granulocyte colony-stimulating factor (G-CSF), tacrolimus, everolimus, sirolimus, etc. ② Use of high-dose corticosteroids (e.g., continued use of prednisolone at a dose of ≥2 mg/kg/day in subjects weighing \<10 kg for 14 days or longer or at a dose of ≥20 mg/day in subjects weighing ≥10 kg for 14 days or longer). However, inhaled, intranasal, or topical corticosteroids are permitted regardless of their dose. 11. Prior use of immunoglobulin or blood products within 3 months prior to screening or their anticipated use during the study 12. Took antipyretics, analgesics, or non-steroidal anti-inflammatory drugs (NSAIDs) within 4 hours prior to vaccination with the IP 13. Participated in another clinical study within 6 months prior to screening 14. Determined ineligible based on other clinically significant medical or psychiatric findings by the investigator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Korea University ANSAN Hospital
Ansan-si, Gyeonnggi-do, 15355, South Korea
-
The Catholic University of Korea, Bucheon St. Mary's Hospital
Bucheon-si, Gyeonnggi-do, 15355, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a chewable postbiotic tablet keep plaque and gum inflammation at bay?
- Can a new oral drug safely help older adults manage weight?
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Green tech or hidden stress? bus Drivers' hearts monitored behind the wheel
- Shout it out: can growls and screams raise pain tolerance?
- Scientists probe why brain stimulation works for some and not others